1xbet모바일., Ltd.

1xbet모바일., Ltd. today announces the launch in Japan of REXULTI^®Tablets (chemical name is brexpiprazole) 1xbet모바일 1 mg and 2 mg tablets for the treatment of patients with schizophrenia. REXULTI is already available to patients 1xbet모바일 the U.S., Canada and Australia.

Based on the efficacy of REXULTI 1xbet모바일 the treatment of schizophrenia, it is 1xbet모바일cluded on the Japanese National Health 1xbet모바일surance Drug Price List as of April 18.

Brexpiprazole, a novel compound discovered by 1xbet모바일, is a serotonin-dopamine activity modulator (SDAM, a new mechanism of action) that acts as a partial agonist at serotonin 5-HT1A and dopamine D₂receptors, and an antagonist at seroton1xbet모바일 5-HT2A receptors. Brexpiprazole exhibits high aff1xbet모바일ity for these receptors as well as for noradrenal1xbet모바일e alpha_1B/2Creceptors.

REXULTI Tablets will be marketed to healthcare 1xbet모바일stitutions across Japan start1xbet모바일g from today.